Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate.
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cyclophosphamide
/ adverse effects
Diagnosis, Differential
Doxorubicin
/ adverse effects
Hepatitis B
/ diagnosis
Hepatitis B virus
/ physiology
Humans
Leuprolide
/ adverse effects
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Male
Prednisone
/ adverse effects
Rituximab
/ adverse effects
Vincristine
/ adverse effects
Virus Activation
LH-RH agonist
R-CHOP
hepatitis B virus reactivation
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 May 2020
01 May 2020
Historique:
pubmed:
21
1
2020
medline:
6
10
2020
entrez:
21
1
2020
Statut:
ppublish
Résumé
An 88-year-old man was admitted for elevated liver enzyme levels. Nine years earlier, the patient had been diagnosed with diffuse large B-cell lymphoma (DLBCL) and undergone rituximab, cyclophosphamide, doxorubicin hydrochloride, oncovin, prednisone (R-CHOP) therapy. This patient previously had had a hepatitis B virus (HBV) infection before chemotherapy. After the chemotherapy, he was administered an luteinizing hormone-releasing hormone (LHRH) agonist for prostate cancer. We diagnosed him with HBV reactivation because of positive serum HBV-DNA. HBV reactivation can occur a long time after chemotherapy, particularly if another treatment with immunity-altering drugs is added. In such cases, additional surveillance may be required to detect HBV reactivation.
Identifiants
pubmed: 31956202
doi: 10.2169/internalmedicine.3805-19
pmc: PMC7270765
doi:
Substances chimiques
R-CHOP protocol
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Leuprolide
EFY6W0M8TG
Prednisone
VB0R961HZT
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1163-1166Références
Hepatology. 2016 Jan;63(1):261-83
pubmed: 26566064
Clin Gastroenterol Hepatol. 2006 Sep;4(9):1076-81
pubmed: 16861051
J Immunol. 2009 May 1;182(9):5846-54
pubmed: 19380833
Intern Med. 2017;56(1):115-118
pubmed: 28049989
Br J Cancer. 2004 Apr 5;90(7):1306-11
pubmed: 15054446
Eur J Haematol. 2001 Jul;67(1):45-50
pubmed: 11553266
Intern Med. 2019 Feb 1;58(3):375-380
pubmed: 30210131
World J Hepatol. 2015 May 8;7(7):954-67
pubmed: 25954478
Hepatology. 2001 Dec;34(6):1225-41
pubmed: 11732013
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
J Clin Oncol. 2014 Nov 20;32(33):3736-43
pubmed: 25287829
Hepatol Int. 2016 Jan;10(1):1-98
pubmed: 26563120
J Clin Oncol. 2009 Feb 1;27(4):605-11
pubmed: 19075267
Transpl Immunol. 2010 Oct;24(1):76-81
pubmed: 20692342
Curr Opin Immunol. 2009 Aug;21(4):454-9
pubmed: 19608394
Hepatol Res. 2015 Dec;45(12):1220-7
pubmed: 25627550
Gastroenterology. 2006 Jul;131(1):59-68
pubmed: 16831590
Hepatol Res. 2014 Jan;44 Suppl S1:1-58
pubmed: 24397839
Br J Haematol. 2009 Mar;144(6):969-70
pubmed: 19120363
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875